Cynosure Inc. (NASDAQ:CYNO) shares traded up 4.9% during trading on Wednesday . The company traded as high as $50.83 and last traded at $50.74, with a volume of 294,514 shares trading hands. The stock had previously closed at $48.36.

A number of research analysts have recently commented on the company. Brean Capital restated a “buy” rating on shares of Cynosure in a research note on Wednesday, April 27th. Zacks Investment Research upgraded Cynosure from a “sell” rating to a “hold” rating in a research note on Wednesday. Maxim Group raised their target price on Cynosure from $52.00 to $60.00 and gave the company a “buy” rating in a research note on Tuesday, April 26th. Finally, Leerink Swann restated a “buy” rating on shares of Cynosure in a research note on Wednesday, April 27th. One research analyst has rated the stock with a hold rating and six have given a buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $51.20.

The firm’s 50-day moving average price is $48.95 and its 200-day moving average price is $43.64. The company has a market capitalization of $1.23 billion and a P/E ratio of 64.43.

Cynosure (NASDAQ:CYNO) last announced its quarterly earnings results on Tuesday, April 26th. The company reported $0.19 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.14 by $0.05. The firm earned $94.70 million during the quarter, compared to analysts’ expectations of $85.78 million. During the same quarter in the previous year, the firm posted $0.15 EPS. The firm’s revenue for the quarter was up 26.4% on a year-over-year basis. On average, equities research analysts forecast that Cynosure Inc. will post $1.29 earnings per share for the current year.

In related news, CFO Timothy W. Baker sold 39,857 shares of the business’s stock in a transaction that occurred on Thursday, April 14th. The stock was sold at an average price of $45.02, for a total value of $1,794,362.14. Following the completion of the sale, the chief financial officer now owns 8,107 shares in the company, valued at $364,977.14. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Douglas J. Delaney sold 24,488 shares of the business’s stock in a transaction that occurred on Thursday, April 14th. The shares were sold at an average price of $45.02, for a total value of $1,102,449.76. Following the completion of the sale, the vice president now owns 8,100 shares of the company’s stock, valued at approximately $364,662. The disclosure for this sale can be found here.

A number of hedge funds recently bought and sold shares of CYNO. Rhumbline Advisers raised its stake in Cynosure by 7.3% in the fourth quarter. Rhumbline Advisers now owns 29,195 shares of the company’s stock worth $1,304,000 after buying an additional 1,980 shares in the last quarter. EAM Investors LLC raised its stake in Cynosure by 14.0% in the fourth quarter. EAM Investors LLC now owns 34,265 shares of the company’s stock worth $1,531,000 after buying an additional 4,208 shares in the last quarter. California State Teachers Retirement System raised its stake in Cynosure by 1.6% in the fourth quarter. California State Teachers Retirement System now owns 41,020 shares of the company’s stock worth $1,832,000 after buying an additional 646 shares in the last quarter. Lapides Asset Management LLC raised its stake in Cynosure by 6.4% in the fourth quarter. Lapides Asset Management LLC now owns 58,500 shares of the company’s stock worth $2,613,000 after buying an additional 3,500 shares in the last quarter. Finally, Sei Investments Co. raised its stake in Cynosure by 91.4% in the fourth quarter. Sei Investments Co. now owns 123,258 shares of the company’s stock worth $5,506,000 after buying an additional 58,873 shares in the last quarter.

Cynosure Inc develops and markets aesthetic treatment systems that enable plastic surgeons, dermatologists and other medical practitioners to perform procedures to remove hair, treat vascular and benign pigmented lesions, remove multi-colored tattoos, revitalize the skin, liquefy and remove unwanted fat through laser lipolysis, reduce cellulite, clear nails infected by toe fungus, ablate sweat glands and improve vaginal health.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.